Get the latest news, insights, and market updates on BNTX (BioNTech SE). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
BioNTech SE (BNTX) Rallying on Solid Oncology Strategy
BioNTech SE (NASDAQ:BNTX) is one of the best stocks to buy and hold for the next 6 months. On February 2, research firm Leerink Partners downgraded BioNTech SE (NASDAQ:BNTX) to a Market Perform from an Outperform and set a $113 price target. The downgrade is in response to the stock rallying from its December lows […] Feb 19, 2026 - $BNTX
Monkeypox Market Competitive Landscape 2026: Comprehensive Insights About 8+ Companies and 10+ Drugs
Emerging opportunities in the monkeypox treatment and prevention market include innovative vaccine developments by companies such as Bavarian Nordic, BioNTech, and Moderna. The focus is on mRNA-based vaccines and modified vaccines, with numerous clinical trials and strategic collaborations underway to enhance public health responses globally.Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Monkeypox - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The "Monkeypox Feb 18, 2026 - $BNTX
Bristol-Myers Squibb Resets Pipeline With RNA Deals And Cost Focus
Bristol-Myers Squibb (NYSE:BMY) has outlined a broad pipeline refresh that includes multiple recent product launches and the announcement of a new R&D facility. The company has agreed to acquire Orbital Therapeutics, expanding its presence in RNA based medicines. New collaborations with BioNTech and Philochem target next generation cancer and immunology treatments. Management has paired these moves with plans for major cost savings and added manufacturing capacity. Bristol-Myers Squibb,... Feb 13, 2026 - $BNTX
BioNTech Adds Chief People Officer To Support Oncology Growth Plans
BioNTech (NasdaqGS:BNTX) has appointed Kylie Jimenez as Chief People Officer. The new executive role is designed to support BioNTech's goal of becoming a multi product oncology company by 2030. This leadership change reflects a focus on global talent, culture, and organizational scale beyond COVID 19 vaccines. For you as an investor, this move highlights how BioNTech is positioning itself within oncology, an area that remains a key focus for many large biopharma players. The company, best... Feb 3, 2026 - $BNTX
BioNTech (BNTX) Valuation Check After Leerink Downgrade And Cooling Cancer Vaccine Optimism
BioNTech (NasdaqGS:BNTX) shares came under pressure after Leerink Partners downgraded the stock, citing limited near term upside from cancer vaccine data, particularly after a recent 24% rally. See our latest analysis for BioNTech. The downgrade comes after a strong 30 day share price return of 17.64% and an 8.51% gain over 90 days. However, the 1 year total shareholder return of 5.07% and 3 year total shareholder return of 19.30% indicate that longer term performance has been weaker. This... Feb 2, 2026 - $BNTX
Goldman Sachs Picks 2 Stocks That Let Investors Buy the Dip or Ride the Momentum
In stock trading, wins and losses hinge on countless moving parts, but choosing the right strategy can tip the odds in your favor. That sounds simple enough in theory, yet in practice, it’s anything but. To see why, consider two of the market’s most popular – and opposing – approaches: buying the dip and riding momentum. Both do exactly what their names imply. Buying the dip means scooping up beaten-down stocks that still boast solid fundamentals. Riding momentum, on the other hand, is about jum Jan 31, 2026 - $BNTX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple